Home›Stock Screener›Fredun Pharmaceuticals›Financial Statements

Fredun Pharmaceuticals Financial Statements

3 Years of Data
2026 - 2024

Fredun Pharmaceuticals financial statements. In FY2026, Fredun Pharmaceuticals (FREDUN) reported revenue ₹266 Cr, net profit ₹19 Cr and EPS ₹10.99, with a net profit margin of 7.1% and ROE of 6.8%. Full financial statements from FY2024 to FY2026 (3 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. See Fredun Pharmaceuticals P/B ratio trends to compare market price against book value per share.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 7.14% 2026 data
EBITDA Margin 15.41% 2026 data
Operating Margin 15.00% 2026 data
Return on Assets 2.96% 2026 data
Return on Equity 6.83% 2026 data

Balance Sheet Ratios

Equity Ratio 43.30% 2026 data
Asset Turnover 0.41 2026 data

FREDUN Revenue, Net Profit & EBITDA — Year-on-Year Growth

FREDUN YoY (Sept 2025 vs Sept 2026) — revenue +84.7%, net profit +111.1%, EBITDA +95.2%, expenses +82.9%. For live price, earnings ratios and company overview, see Fredun Pharmaceuticals stock price NSE.

Revenue Growth
+84.7%
Year-over-Year
Net Profit Growth
+111.1%
Year-over-Year
EBITDA Growth
+95.2%
Year-over-Year
Expense Growth
+82.9%
Year-over-Year
Assets Growth
+31.8%
Year-over-Year
Equity Growth
+97.2%
Year-over-Year
Operating Cash Flow Growth
+170.6%
Year-over-Year
Investing Cash Flow Growth
-1133.3%
Year-over-Year
Financing Cash Flow Growth
+348.1%
Year-over-Year

FREDUN Income Statement — Revenue, EBITDA & Net Profit

Fredun Pharmaceuticals revenue ₹266 Cr, EBITDA ₹41 Cr, net profit ₹19 Cr, EPS ₹10.99 (2026) — net profit margin 7.1%. Explore FREDUN fundamental worth to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Sept 2026 Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Jun 2024 Dec 2024
Revenue 266 210 228 144 165 119 160 0 0 286
Expenses 225 184 196 123 150 103 135 0 0 251
EBITDA 41 26 32 21 15 17 25 0 0 35
Operating Profit Margin % 15.00% 12.00% 14.00% 14.00% 9.00% 14.00% 16.00% 0.00% 0.00% 12.00%
Depreciation 4 3 4 2 2 1 2 0 0 3
Interest 9 15 9 8 8 7 11 0 0 14
Profit Before Tax 30 11 21 13 7 9 14 0 0 20
Tax 11 1 7 3 1 2 4 0 0 7
Net Profit 19 11 13 9 6 7 11 0 0 14
Earnings Per Share (₹) 10.99 19.70 23.82 19.98 12.71 14.33 22.19 0.00 0.00 29.09

FREDUN Balance Sheet — Assets, Liabilities & Shareholders' Equity

FREDUN total assets ₹642 Cr, total equity ₹278 Cr, total liabilities ₹ Cr (2026) — ROE 6.8%.

Years Annual Data ₹ Crores
Particulars 2026 2025
ASSETS
Total Assets 642 487
Current Assets
Fixed Assets 118 53
Capital Work in Progress 0 0
Investments 2 2
Other Assets 522 433
LIABILITIES
Total Liabilities
Current Liabilities 67 18
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 278 141
Share Capital 6 5
Reserves & Surplus 259 137

FREDUN Cash Flow Statement — Operating, Investing & Financing

Fredun Pharmaceuticals operating cash flow ₹12 Cr, investing ₹-74 Cr, financing ₹121 Cr, net cash flow ₹60 Cr (2026).

Periods ₹ Crores
Particulars March 2026 March 2025
Operating Activities 12 -17
Investing Activities -74 -6
Financing Activities 121 27
Net Cash Flow 60 4